Compare Icl Group Ltd (ICL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Smith & Nephew plc — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Smith & Nephew plc for 121 Days on average.
| ICL | SNN | |
|---|---|---|
Market Cap | $6.47B | $11.10B |
Volume | 1,387,140 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $37.17 |
52-Week Low | $4.80 | $26.42 |
Typical Hold Time | 56 Days | 121 Days |
Enterprise Value | $9.11B | $14.13B |
Dividend Yield | 4.11% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.00, down 1.57% on the day. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 earnings of $0.12 per share, beating estimates, but revenue and net income margins have declined from prior years. Valuation ratios like P/E of 20.83 and P/S of 0.84 suggest moderate pricing relative to earnings and sales. A dividend of $0.06 is scheduled for payment in September 2026.
The outlook is mixed. Positive earnings beats and a low EV/EBITDA of 6.68 indicate potential value, but bearish technicals and declining profitability pose risks. Analyst consensus is neutral with a $6.08 price target, implying upside. Key risks include industry headwinds like higher input costs and competitive pressures.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
